NeoSpine first to offer spinal cord stimulation for treatment of painful diabetic neuropathy

292

NeoSpine is now offering spinal cord stimulation (SCS) procedures for the treatment of painful diabetic neuropathy (PDN) via its HFX system—a newly approved nondrug treatment for PDN which, according to NeoSpine, is the only SCS system approved by the US Food and Drug Administration (FDA) with a specific indication to treat the condition.

HFX includes a Senza spinal cord stimulation system and support services for the treatment of chronic pain. Patients are implanted with the Senza system and programmed to include a frequency of 10 kHz.

The device is implanted during a quick and minimally invasive procedure, and then begins delivering mild pulses at a high frequency directly to the spinal cord to stop pain signals from reaching the brain.

Kathy Wang, pain management specialist at NeoSpine, said: “People with PDN know it to be a cruel addition to the chronic disease they must fight every day. HFX for PDN offers a new option to alleviate this agonising and persistent sensation.

“There is no other therapy like this, and to offer it to people here at NeoSpine is an absolute privilege. I believe this can make a real difference for my patients with PDN.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here